▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3696 by analyst upside · 2026-06-27
BIO
Bio-Rad Laboratories, Inc.
Healthcare · Market Cap $8B · P/E 50.1x
ANALYST PRICE TARGET
-1.3%
implied upside to consensus target
Current Price $300.79
Consensus Target $297.0
Bull Target $320.0
Bear Target $275.0
Analysts Covering 5
ANALYST CONSENSUS - HOLD
Strong Buy
0
Buy
1
Hold
4
Sell
0
52-Week Low $236.73
52-Week High $343.12
YTD Return -1.5%
FUNDAMENTALS
Market Cap $8B
P/E Ratio (TTM) 50.1x
Forward P/E 30.9x
EPS (TTM) $6.00
PEG Ratio 4.01
Dividend Yield N/A
Revenue (TTM) $2.6B
Profit Margin 6.5%
52-WEEK RANGE
52-Week Low $236.73
52-Week High $343.12
Current Price $300.79
Bear Target $275.0
Bull Target $320.0
● Now $300.79 ● Target $297.0
TRADING DATA
Avg Volume 381K
YTD Return -1.5%
Analyst Count 5
Consensus Hold
Upside to Target -1.3%
Last Updated 2026-06-27

ANALYST SUMMARY

Bio-Rad Laboratories, Inc. (BIO) is currently trading at $300.79 with a Wall Street consensus price target of $297.0, which is 1.3% below the current price over the next 12 months. 5 analysts currently cover BIO, with a consensus rating of Hold - 20% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $320.0, while the most cautious has a target of $275.0.

BIO operates in the Healthcare sector with a market capitalisation of $8B. The stock is down 1.5% year-to-date and is currently trading near the upper end of its 52-week range of $236.73 – $343.12.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

MASI +0.0%
Masimo Corporation
$9B · P/E 44.4x · Hold
ALKS -12.6%
Alkermes plc
$9B · P/E 61.2x · Buy
TGTX -7.4%
TG Therapeutics, Inc.
$9B · P/E 19.5x · Buy
HSIC +3.7%
Henry Schein, Inc.
$10B · P/E 25.3x · Buy
QGEN +11.6%
Qiagen N.V.
$8B · P/E 20.1x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for BIO, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Wells Fargo — Reiterated
Equal-Weight → Equal-Weight 2026-05-01 Building track record
Citigroup ↓ Downgrade
Buy → Neutral 2026-04-07 Building track record
Wells Fargo — Reiterated
Equal-Weight → Equal-Weight 2026-02-16 Building track record
Citigroup — Reiterated
Buy → Buy 2025-10-30 Building track record
Wells Fargo — Reiterated
Equal-Weight → Equal-Weight 2025-10-30 Building track record
RBC Capital — Reiterated
Outperform → Outperform 2025-08-01 Building track record
Wells Fargo — Reiterated
Equal-Weight → Equal-Weight 2025-08-01 Building track record
Wells Fargo — Reiterated
Equal-Weight → Equal-Weight 2025-06-09 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
43
out of 100
Coverage depth
14/30
Consensus clarity
27/30
Vote unanimity
0/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →